• Je něco špatně v tomto záznamu ?

One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases

J. Kosťun, KM. Ismail, M. Pešta, R. Slunečko, P. Stráník, V. Smoligová, J. Presl

. 2024 ; 7 (12) : e70082. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003120

Grantová podpora
Cooperatio program, MATC science area
LX22NPO5102 National Institute for Cancer Research-NICR
European Union-Next Generation EU

AIMS: Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue. METHODS AND RESULTS: Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period. CONCLUSION: The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003120
003      
CZ-PrNML
005      
20250206104042.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cnr2.70082 $2 doi
035    __
$a (PubMed)39724456
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kosťun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic $1 https://orcid.org/0000000340779031 $7 xx0234946
245    10
$a One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases / $c J. Kosťun, KM. Ismail, M. Pešta, R. Slunečko, P. Stráník, V. Smoligová, J. Presl
520    9_
$a AIMS: Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue. METHODS AND RESULTS: Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period. CONCLUSION: The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory endometria $x genetika $x patologie $x chirurgie $7 D016889
650    12
$a techniky amplifikace nukleových kyselin $x metody $7 D021141
650    12
$a sentinelová uzlina $x patologie $x chirurgie $7 D000071036
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a následné studie $7 D005500
650    12
$a staging nádorů $7 D009367
650    12
$a biopsie sentinelové lymfatické uzliny $7 D021701
650    _2
$a lymfatické metastázy $x patologie $x diagnóza $7 D008207
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dospělí $7 D000328
650    _2
$a lokální recidiva nádoru $x patologie $x genetika $x epidemiologie $7 D009364
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Ismail, Khaled M $u Department of Gynaecology and Obstetrics and Biomedical Center, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
700    1_
$a Pešta, Martin $u Department of Immunochemistry, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň- Bory, Czech Republic $1 https://orcid.org/0000000181870566 $7 xx0073915
700    1_
$a Slunečko, Robert $u Šikl's Department of Pathology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
700    1_
$a Stráník, Petr $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
700    1_
$a Smoligová, Vendula $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
700    1_
$a Presl, Jiří $u Department of Gynaecology and Obstetrics, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Plzeň-Lochotín, Czech Republic
773    0_
$w MED00209152 $t Cancer reports $x 2573-8348 $g Roč. 7, č. 12 (2024), s. e70082
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39724456 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104038 $b ABA008
999    __
$a ok $b bmc $g 2263086 $s 1239127
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 7 $c 12 $d e70082 $e - $i 2573-8348 $m Cancer reports $n Cancer Rep (Hoboken) $x MED00209152
GRA    __
$p Cooperatio program, MATC science area
GRA    __
$a LX22NPO5102 $p National Institute for Cancer Research-NICR
GRA    __
$p European Union-Next Generation EU
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...